Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow TELA Bio, Inc.

Get SEC filing alerts via email and in your feed for TELA Bio, Inc.

TELA

TELA Bio, Inc.

About TELA Bio, Inc.

TELA Bio, Inc. develops innovative soft-tissue reconstruction solutions, primarily through its OviTex portfolio, which combines biologic matrices with polymer reinforcement for hernia repair and plastic surgery. Its products aim to improve clinical outcomes, reduce complications, and lower costs. The company partners with healthcare providers, leverages extensive clinical data, and holds proprietary IP to address unmet needs in tissue repair markets worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from TELA Bio, Inc.

1
1
TELA Bio, Inc. TELA Bio Reports 3% Revenue Growth to $19.1 Million in Q1 2026

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
TELA Bio, Inc. TELA Bio, Inc. Reports 16% Revenue Growth to $80.3 Million for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
TELA Bio, Inc. TELA Bio Reports 9% Revenue Growth to $20.7 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
TELA Bio, Inc. TELA Bio Reports 26% Revenue Growth to $20.2 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
TELA Bio, Inc. TELA Bio Reports 12% Revenue Growth to $18.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
TELA Bio, Inc. TELA Bio Reports 19% Revenue Growth to $69.3 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
TELA Bio, Inc. TELA Bio Reports 26% Revenue Growth, Reduced Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments